Nordic Capital Partners with Minerva Imaging to Drive Growth in Radiopharmaceuticals

In an ambitious move aimed at scaling operations and enhancing expertise within the rapidly evolving radiopharmaceutical market, Nordic Capital has announced a partnership with Minerva Imaging. This collaboration marks a significant stride towards bolstering Minerva's growth, aiming to solidify the company’s position as a global leader in radiopharmaceutical services.

Minerva Imaging, known for its science-driven approach, specializes in Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) services. The company is particularly focused on developing targeted radioligand therapies, which have emerged as a transformative avenue in cancer treatments. The partnership will enable Minerva to amplify its capabilities and support a wider array of clients, from pre-clinical research to clinical development.

With a robust team of over 150 skilled professionals, a significant portion holding PhDs, Minerva has established a reputation for scientific excellence. Their facilities in Denmark deliver a fully integrated platform that combines advanced oncology and cardiovascular disease models with extensive service offerings. This unique combination allows Minerva to provide tailored solutions to some of the world’s leading pharmaceutical and biotechnology firms.

The global radiopharmaceutical market is on the brink of substantial growth, driven by the increasing prevalence of cancer and a rising demand for precision medicine. As the market expands, Minerva, through its partnership with Nordic Capital, is strategically positioned to scale its operations and refine its scientific capabilities, ensuring maximum support to clients during crucial developmental stages.

Andreas Kjaer, Chairman and Founder of Minerva, expressed pride in the company’s accomplishments and optimism for the future. He stated, “We are incredibly proud of Minerva's progress. Our innovative solutions make a tangible impact for our collaborators and customers, with the ultimate goal of helping patients. Partnering with Nordic Capital, with its extensive expertise and strong network, will allow us to continue this journey together.”

Moreover, Carsten H. Nielsen, CEO and Founder of Minerva, highlighted the mutual benefits of the partnership. He noted, “Together with Nordic Capital, we can support innovation and fuel our growth through organic expansion and selective strategic acquisitions. Their backing enables us to enrich and extend our service offerings to our valued customers.”

Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory, conveyed his enthusiasm for the partnership, stating, “Minerva is a frontrunner in its field. Their rigorous scientific approach and well-established platform position the company strongly for future growth in the sector. We believe Nordic Capital is uniquely positioned to assist Minerva in its next phase of growth and in expanding its service offerings.”

With over three decades of experience, Nordic Capital’s commitment to fostering growth in the healthcare sector is evident. Their Evolution platform, which targets middle-market growth companies in Northern Europe, aligns seamlessly with Minerva's objectives of expansion and refinement of their offerings. Notably, this is the eleventh investment made by Nordic Capital Evolution since 2021, demonstrating their dedication to advancing healthcare innovation.

Although the specific terms of the investment have not been disclosed, the transaction is expected to be completed in the third quarter of 2025, pending customary regulatory approvals. The collaboration between Nordic Capital and Minerva Imaging promises to usher in a new era of growth within the radiopharmaceutical landscape, with the potential to significantly enhance patient outcomes in cancer treatment.

For more information on Minerva Imaging, visit Minerva Imaging or for inquiries about Nordic Capital, their official website can be found at Nordic Capital.